Evidence map›Paper›PMID 31903104›Full record

ArticleTheranostics2020

Liver-targeted delivery of TSG-6 by calcium phosphate nanoparticles for the management of liver fibrosis.

Min Wang, Miao Zhang, Lianhua Fu, Jing Lin, Xinmin Zhou, Pinghong Zhou, Peng Huang, Hao Hu, Ying Han

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Theranostics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed, 1 pooled it
2.7field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

41 citing papers in PubMed, 1 synthesis or guideline pooled it, 75 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Nanomedicines in the Treatment of Liver Fibrosis: A Review.International journal of nanomedicine · 2025
    Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Prospective therapeutics for intestinal and hepatic fibrosis.Bioengineering & translational medicine · 2023
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Min WangDepartment of Gastroenterology, Hepatology and Nutrition, Shanghai Children's Hospital, Shanghai Jiao Tong University, Shanghai 200062, China.
Miao ZhangXijing Hospital of Digestive Diseases, State Key Laboratory of Cancer Biology, Fourth Military Medical University, Xi'an 710032, China.
Lianhua FuMarshall Laboratory of Biomedical Engineering, International Cancer Center, Laboratory of Evolutionary Theranostics (LET), School of Biomedical Engineering, Shenzhen University Health Science Center, Shenzhen, 518060, China.
Jing LinMarshall Laboratory of Biomedical Engineering, International Cancer Center, Laboratory of Evolutionary Theranostics (LET), School of Biomedical Engineering, Shenzhen University Health Science Center, Shenzhen, 518060, China.
Xinmin ZhouXijing Hospital of Digestive Diseases, State Key Laboratory of Cancer Biology, Fourth Military Medical University, Xi'an 710032, China.
Pinghong ZhouEndoscopy Center of Zhongshan Hospital, Fudan University, Shanghai 200032, China.
Peng HuangMarshall Laboratory of Biomedical Engineering, International Cancer Center, Laboratory of Evolutionary Theranostics (LET), School of Biomedical Engineering, Shenzhen University Health Science Center, Shenzhen, 518060, China.
Hao HuEndoscopy Center of Zhongshan Hospital, Fudan University, Shanghai 200032, China.
Ying HanXijing Hospital of Digestive Diseases, State Key Laboratory of Cancer Biology, Fourth Military Medical University, Xi'an 710032, China.
Air Force Medical University · CNShenzhen University Health Science Center · CNZhongshan Hospital · CNXijing Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mesenchymal stem cells (MSCs) transplantation is a promising antifibrotic strategy but facing clinical controversies. Inspired by advances in nanomedicine, we aimed to bypass these clinical barriers of MSCs by identifying the key antifibrotic molecule of MSCs and developing a specific liver-targeting nanocarrier.

Indexed as

Cell Adhesion MoleculesAnimalsCalcium PhosphatesCytokinesDrug CarriersHumansLiverLiver CirrhosisMacrophagesMaleMatrix Metalloproteinase 12MiceMice, Inbred C57BLNanoparticlesRecombinant ProteinsSerum Albumin, BovineCalcium PhosphatesCell Adhesion MoleculesCytokinesDrug Carriersmatrix metallopeptidase 12, mouseMatrix Metalloproteinase 12Recombinant ProteinsSerum Albumin, BovineTNFAIP6 protein, humanbovine serum albumin (BSA)Calcium phosphate nanoparticleLiver fibrosisLiver targeting deliverymatrix metalloproteinase 12 (MMP12)Tumor necrosis factor-stimulated gene 6 (TSG-6)

Identifiers

PMID31903104
PMCPMC6929629
OpenAlexW2982585013

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.